SCHEMBL25308596

SCHEMBL25308596

COc1ccn(C2CN(C(=O)OC(C)(C)C)C2)n1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CA P42336 2/20 0.42
PDE4B Q07343 1/20 0.41
ALDH1A1 P00352 1/20 0.40
CACNB4 O00305 1/20 0.40
CACNA1A O00555 1/20 0.40
CACNA1G O43497 1/20 0.40
CACNG3 O60359 1/20 0.40
CACNA1F O60840 1/20 0.40
CACNA1H O95180 1/20 0.40
CACNB3 P54284 1/20 0.40
CACNA2D1 P54289 1/20 0.40
CACNG7 P62955 1/20 0.40
CACNA1B Q00975 1/20 0.40
CACNA1D Q01668 1/20 0.40
CACNB1 Q02641 1/20 0.40
CACNG1 Q06432 1/20 0.40
CACNB2 Q08289 1/20 0.40
CACNA1S Q13698 1/20 0.40
CACNA1C Q13936 1/20 0.40
CACNA1E Q15878 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31056160 0.85 FPR2 (0.42) GPR119NR1H2NAMPTUSP30RORC
SCHEMBL25432161 0.84 NR1H2 (0.40) PDE4BGPR119NR1H2NAMPTUSP30
SCHEMBL255140 0.83 NR1H2 (0.43) PIK3CAGPR119NR1H2NAMPTUSP30
SCHEMBL21063582 0.82 NR1H2 (0.42) PDE4BALDH1A1GPR119NR1H2NAMPT
SCHEMBL21063625 0.82 USP30 (0.41) PDE4BGPR119NR1H2NAMPTUSP30
SCHEMBL15293710 0.81 ALDH1A1 (0.44) ALDH1A1GPR119NR1H2NAMPTUSP30
SCHEMBL26090665 0.81 NR1H2 (0.38) PDE4BGPR119NR1H2NAMPTUSP30
SCHEMBL30618283 0.77 MAPT (0.44) PIK3CAALDH1A1GPR119
SCHEMBL25434224 0.77 MAPT (0.44) PIK3CAALDH1A1GPR119
SCHEMBL16714488 0.75 SRC (0.41) PIK3CAPDE4BALDH1A1GPR119NR1H2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250215029-A1 STAT MODULATORS AND USES THEREOF RECLUDIX PHARMA, INC. 2025-07-03 US disclosed
EP-4463459-A1 STAT MODULATORS AND USES THEREOF Recludix Pharma, Inc. (US) 2024-11-20 EP disclosed
CN-118804917-A STAT modulators and uses thereof 瑞克鲁迪克斯制药股份有限公司 2024-10-18 CN disclosed
WO-2023133336-A1 STAT MODULATORS AND USES THEREOF RECLUDIX PHARMA, INC. (US) 2023-07-13 WO disclosed
WO-2023133336-A1 STAT MODULATORS AND USES THEREOF RECLUDIX PHARMA, INC. (US) 2023-07-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250215029-A1 STAT MODULATORS AND USES THEREOF STAT6, STAT3, STAT5A PIK3CA 598/4885PDE4B 863/4885ALDH1A1 2707/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.